SKIN & AESTHETICS / COMPARISON
Three compounds, three completely different evidence problems
Shared shelf, shared vocabulary, almost nothing else in common. What separates these three is not potency — it is what has actually been measured, and in whom.
The short version
These three sit together because people search for them together, not because they resemble each other. One is a mixed vial of three peptides. One is a single small copper-carrying peptide with a cosmetic-ingredient history. One is a synthetic hormone analog that switches on pigment production body-wide.
The most useful way to line them up is not by strength but by how much of each claim has actually been tested in people, and how much is borrowed. On that axis they separate cleanly: GHK-Cu has small controlled trials of the thing itself; Melanotan II has one tiny controlled trial about something unrelated to appearance, plus a substantial harm literature; the GLOW blend has no trial of the blend at all.
The comparison matrix
| Dimension | GLOW (research blend) | GHK-Cu | Melanotan II |
|---|---|---|---|
| What it is | Co-formulated vial of three peptides: GHK-Cu, BPC-157, TB-500 | Single tripeptide (Gly-His-Lys) chelated to a copper(II) ion | Cyclic, D-Phe-substituted seven-amino-acid analog of alpha-MSH |
| Mechanism | Three parallel mechanisms: matrix building, angiogenesis, cell migration [3][4][7] | Copper chaperone plus direct fibroblast signalling; matrix synthesis and MMP rebalancing [4][5] | Non-selective melanocortin receptor agonist, MC1R through MC5R [15] |
| Studied for | Nothing, as a blend; constituents studied for wound, tendon and skin repair [1][6] | Wrinkles, skin quality, hair count, wound healing [4][8][10] | Erectile dysfunction in a 10-man crossover; appetite in rodents [13][16] |
| Strongest human evidence | None for the combination; a 2026 review names all three constituents and calls human safety data scarce [1] | Small controlled topical studies plus a 45-man randomized trial of a combination formulation [8][10] | One double-blind crossover in 10 men; no completed Phase II or III [16] |
| Route in the evidence | Subcutaneous injection of an unstandardised mixture | Topical for the cosmetic evidence; injection is unstudied in humans [11] | Subcutaneous injection [12][16] |
| Regulatory status | No approved product; two constituents unapproved and prohibited in sport | Topical Copper Tripeptide-1 is a legal cosmetic ingredient; systemic use unapproved | Approved nowhere; multiple national regulator warnings |
| Key caution | Untested combination, mismatched kinetics, anti-doping exposure [1][2] | Irritation topically; copper handling and unstudied injectable use systemically [8] | Melanocytic lesion change, renal and vascular case reports, unregulated product [12][14] |
Mechanism: three different levers
GHK-Cu pulls a structural lever. It signals fibroblasts to build collagen, elastin, glycosaminoglycans and decorin while rebalancing the enzymes that degrade them, and it carries the copper those cross-linking enzymes require [4][5].
GLOW pulls three levers at once by design — the structural one from GHK-Cu, a vascular one from BPC-157 through VEGFR2 signalling [3], and a cell-migration one from the thymosin beta-4 fragment [7]. Complementary in theory; never characterised together in practice.
Melanotan II pulls a hormonal lever, and not selectively. Activating MC1R produces pigment; activating MC3R, MC4R and MC5R at the same time produces appetite suppression, sexual effects and vascular changes, because one molecule is addressing the whole receptor family [15].
Evidence maturity: the gap is the story
Ranking by controlled human data produces a short list and a long silence.
GHK-Cu leads, modestly: a 2025 review of topical use reports procollagen synthesis increased in 70% of treated subjects against 50% for vitamin C and 40% for retinoic acid [8], and a 6-month trial in 45 men found significant hair-count increases against placebo — though of a 5-aminolevulinic acid plus GHK combination rather than the peptide alone [10].
Melanotan II has exactly one controlled human study of consequence, in 10 men, measuring erectile response rather than anything to do with appearance [16]. Everything cosmetic about it is mechanism plus case reports.
GLOW has zero. Its constituent literature is real — a transected rat Achilles tendon healed faster with BPC 157 [6], thymosin beta-4 raised re-epithelialization by 42% at day 4 and 61% at day 7 in rat wounds [7] — but none of it is a study of the vial being sold.
Regulatory status differs more than anything else
This is where the three separate most sharply, and it is the practical difference most often flattened in write-ups.
Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK with a long consumer safety record — a genuinely different legal object from an injectable research chemical, even when the molecule is the same.
BPC-157 and TB-500, two-thirds of the GLOW vial, are unapproved research chemicals; BPC-157 was placed by the FDA in 2023 in a category of bulk drug substances identified as not eligible for pharmacy compounding pending further evaluation, and both are prohibited in sport at all times.
Melanotan II has no approved indication anywhere, and the FDA, TGA, MHRA and HPRA have all issued warnings about melanotan products. Notably, two regulator-approved drugs in the same chemical family — afamelanotide and bremelanotide — are frequently confused with it; neither approval extends to melanotan II [15].
The caution that matters most for each
For GHK-Cu, topically, the realistic risk is tolerability: irritation, and losing the product's effect by layering it with low-pH vitamin C or exfoliating acids [8]. Systemically it is a different question entirely, with no validated human pharmacokinetic basis and a mechanistic copper-accumulation concern for anyone with a copper-handling condition [11].
For GLOW, the caution is structural rather than toxicological: an unstandardised mixture of three peptides with different clearance rates, no combined safety data, and an anti-doping problem baked in for tested athletes [1][2].
For Melanotan II, the cautions are documented events, not extrapolations — changing and newly appearing moles, case-reported melanoma, renal infarction and rhabdomyolysis, priapism, and unregulated product of unknown content [12][14]. That is a categorically different kind of risk from an irritated cheek.